Novel biomarkers for lysosomal storage disorders (LSDs)

ENABLING DIAGNOSIS, PREDICTION & THERAPY MONITORING

Biomarkers transform the management of LSDs

- Easy to be analyzed using DBS (dried blood spots) technology
- Linked to clinical manifestation
- Quantify easily and reliably in clinical samples
- Reflect realistically the burden of the disease
- Elucidate the molecular pathogenesis of the disease
- Reflect the therapeutic measure outcomes

Biomarkers transform the management of LSDs

Novel mass-spectrometry (MS) based biomarkers for LSDs

- Proven world-class expertise in the identification of new biomarkers, validated in epidemiological clinical trials
- Established MS-based proprietary biomarker tests for Gaucher, Niemann-Pick type A/B and C, Fabry and Farber
- Optimized and facilitated sample logistics with our CE labeled filtercards, CentoCard®
Benefits of CENTOGENE’s biomarkers

**ANALYTICAL SUPERIORITY**
- Simplified logistics and analysis in blood, plasma and DBS (CentoCard®)
- High sensitivity and specificity

**CLINICAL SUPERIORITY**
- Shortest TAT
- Interpretation by scientific and medical experts

Application of CENTOGENE’s biomarkers: diagnosis, therapy monitoring and evaluation

For example, lyso-glucosylsphingosine (Lyso-Gb1) is an excellent biomarker used by our scientists for the accurate screening, diagnosis and follow-up of Gaucher disease.

**LYSO-GB1 QUANTIFICATION IN GAUCHER PATIENTS AND CARRIERS**

Our biomarkers guarantee more personalized LSD diagnostics and tailored treatments.

**LYSO-GB1 FOLLOW-UP STUDY FOR A PATIENT UNDER ERT FOR MORE THAN 2 YEARS**

CENTOGENE works alongside academic and industrial partners, as well as patient organizations to develop new diagnostic assays and biomarkers that can improve the condition and prospects of patients affected by lysosomal storage disorders.